Skip to content
PeptideWiki.bio

Recovery

Cibinetide

Also called ARA-290, EPO-derived 11-mer

InjectableEvidence AEvery day
Half-life
0.05hours
Typical vial
5 / 10mg
Research amounts
1–8mg

per administration

Common schedule
Every day
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Quick start

Cibinetide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.

Typical dose
1–8 mg per administration
How often
Every day
Where
Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
Time to steady level
~0 hours — about five half-lives
Storage
Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details

A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.

Work out your draw

These numbers are a starting point — change any of them.

Vial label

Copy this into your label printer.

Published research contexts for Cibinetide describe 18 mg per administration. Descriptive only, not a recommendation.

Minutes-scale in plasma; the decay chart is largely illustrative here.

Dosing schedule

How Cibinetide is commonly stepped up, for reference only.

These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.

PhaseAmountFrequencyRoute
Studied daily doseThe amount carried through the 28-day study.4 mgOnce dailySubQ
Range exploredSingle ascending doses of 1, 4 and 8 mg were assessed.1–8 mgOnce dailySubQ

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
0.94× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
0hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • Dahan A et al., Mol Med 2013;19:334Subcutaneous cibinetide (ARA-290) 4 mg once daily for 28 days assessed in sarcoidosis-associated small-fibre neuropathy.
  • Culver DA et al., 2017Subcutaneous cibinetide at 1, 4 and 8 mg once daily assessed over 28 days for corneal nerve-fibre measures.

Next steps

Others in recovery